PeptiDex
Peptide Research Index
Research-backed
Peptide Research Index
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
Also: Mounjaro, Zepbound
Dual Agonist (GLP-1/GIP)Last Updated: April 1, 2026
Tirzepatide (also known as Mounjaro, Zepbound) is a prominently researched experimental compound classified strictly within the Dual Agonist (GLP-1/GIP) framework. Operating primarily through advanced pharmacological pathways, it functions by dual receptor agonism at GLP-1 and GIP receptors for synergistic appetite suppression, improved insulin sensitivity, and enhanced metabolic function. with a documented biological half-life of roughly 120 hours, in preclinical investigative trials and independent academic studies, researchers utilizing Tirzepatide have documented significant, quantifiable biological outcomes, primarily focusing on weight loss, body recomposition, glycemic control. Typical research protocols investigate administering 2500 to 2500mcg via subq pathways 1x/wk. However, it is critically important to understand that while Tirzepatide demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.
Dual receptor agonism at GLP-1 and GIP receptors for synergistic appetite suppression, improved insulin sensitivity, and enhanced metabolic function.
Jastreboff et al. (NEJM): Phase 3 SURMOUNT-1 trial tirzepatide 15mg achieved 22.5% body weight reduction vs 2.4% placebo at 72 weeks in 2,539 adults with obesity.
very strongAronne et al.: 176-week data showing sustained weight loss maintenance with continued tirzepatide treatment 15mg dose maintained -19.7% weight reduction.
very strongMeta-analysis of multiple RCTs confirming tirzepatide significantly reduces BMI, waist circumference, body weight, and HbA1c across diverse patient populations.
very strongFrias et al. (NEJM): SURPASS-1 trial showing tirzepatide reduces HbA1c by up to 2.07% and body weight by 9.5 kg in type 2 diabetes. Superior to semaglutide in head-to-head trials.
very strongFDA-approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). GI side effects common but manageable. Well-studied long-term safety.
⚠️ For educational purposes only. Not medical advice. Consult a healthcare professional before using any peptide.
Start 2.5mg weekly, escalate every 4 weeks: 5mg → 7.5mg → 10mg → 12.5mg → 15mg. Prescription required.
Last updated: 2026-01 · Laws change frequently. Verify current status in your jurisdiction.
Week 1
GI adjustment period; appetite suppression begins
Weeks 2-4
5-8% weight reduction at therapeutic dose
Month 2-3
15-20% body weight reduction at 15mg
Long-term
22.5% weight loss at 72 weeks (SURMOUNT-1); superior to semaglutide in head-to-head
| Side Effect | Incidence | Severity |
|---|---|---|
Nausea From SURMOUNT-1 Phase 3 trial | ~32% of users | moderate |
Diarrhea | ~23% of users | mild |
Vomiting | ~20% of users | moderate |
Constipation | ~18% of users | mild |
Hypoglycemia Risk higher when combined with insulin | ~5% of users | moderate |
Incidence rates sourced from published clinical trial data where available; otherwise based on community research observations.
Finding verified, high-purity Tirzepatide requires rigorous COA verification. We independently evaluate vendors based on third-party HPLC testing, purity thresholds (≥98%), and batch-specific documentation.
View COA-Verified Tirzepatide✓ Third-party tested·✓ US shipping·✓ COA on every batch
Disclosure: PeptiDex may earn a commission from purchases made through affiliate links. This does not affect our editorial independence or recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
Reverse insulin resistance, lower blood glucose, and restore metabolic flexibility
PeptiDex. (2026). Tirzepatide. PeptiDex Research Platform. https://peptidex.app/library/tirzepatide
12 stacks • exact dosages • cycle lengths • printable reference
No spam. Unsubscribe anytime.